<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 07, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02281058</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000699</org_study_id>
    <nct_id>NCT02281058</nct_id>
  </id_info>
  <brief_title>Open-label Pilot Study of Abatacept for the Treatment of Vitiligo</brief_title>
  <official_title>Open-label Pilot Study of Abatacept for the Treatment of Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>Institutional Review Board USA:</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement.  We are
      performing a pilot study for the treatment of new onset or actively progressing vitiligo
      with abatacept to determine if weekly self-injections of medication lead to clinical
      improvement in vitiligo lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abatacept has been shown to decrease T cell activity and reduce symptoms associated with
      rheumatoid arthritis.  Similar pathways have been shown to be involved in vitiligo.
      Therefore, we are recruiting 10 adult patients with active vitiligo who meet specific
      inclusion and exclusion criteria to receive self-administered injections of abatacept weekly
      starting at week 0 and continuing until week 24.  A 32 week follow-up visit will be
      performed to evaluate secondary endpoints as well.  We will be monitoring patients to see if
      skin lesions of vitiligo stop spreading and start to repigment with continued treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in repigmentation with abatacept therapy as measured using the Vitiligo Area and Severity Index (VASI) score</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical safety and rate of adverse events as measured by patient-reported side effects</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage repigmentation with abatacept therapy as measured using the physician's global assessment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on disease-related quality of life as measured using the validated Vitiligo Quality of Life (VitiQOL) tool</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maintenance of repigmentation after stopping therapy</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initial time to repigmentation</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>self-injected subcutaneous biologic medication</description>
    <arm_group_label>intervention group</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant individuals ages 18 and older with a diagnosis of actively progressive
             skin lesions of clinically diagnosed vitiligo covering at 5% or great body surface
             area (defined as development of new lesions or worsening of existing lesions within
             the past 6 months) not receiving immune suppressive treatment.  Both subjects who
             have received at least one therapy in the past  and subjects currently receiving
             treatment at the time of screening will be eligible providing they undergo a wash out
             period prior to starting the study (2 weeks for topical agents and systemic agents
             with short half lives, 1 month for phototherapy)

          -  Women of childbearing potential (WOCBP) must be using an acceptable method of
             contraception to avoid pregnancy throughout the study and for up to 10 weeks after
             the last dose of study drug in such a manner that the risk of pregnancy is minimized

          -  WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity
             25 IU/L or equivalent units of HCG) within 0 to 48 hours before the first dose of
             study drug

          -  Women must not be breast-feeding

          -  Sexually active fertile men must use effective birth control if their partners are
             WOCBP

        Exclusion Criteria:

          -  Pregnant or breastfeeding patients

          -  Patients with segmental, acrofacial, or universal vitiligo

          -  Patients with evidence of poliosis (white hairs) within the majority (&gt;50%) of their
             vitiligo lesions

          -  Patients currently on any other systemic biologic medication, current use of
             Abatacept, or any other systemic biologic medication within 2 months of study (or
             within 5 half-lives of last dose of drug)

          -  Use of systemic immunosuppressive agent within 2 weeks prior to initiation of
             Abatacept

          -  Use of potent topical steroids, topical tacrolimus or pimecrolimus within 2 weeks
             prior to initiation of Abatacept

          -  Use of phototherapy within one month prior to initiation of Abatacept therapy

          -  Patients with a history of chronic obstructive pulmonary disease

          -  History of active Mycobacterium tuberculosis infection (any subspecies) Use of any
             investigational medication within 28 days prior to enrollment or 5 half-lives if
             known (whichever is longer)

          -  Receiving concomitant immune modulating therapy (see concomitant medications, section
             8.6).  Subjects receiving such agents at screening may be eligible to enroll
             following a washout period of 2 weeks for topical agents and systemic agents with
             short half lives

          -  Subjects who are impaired, incapacitated, or incapable of completing study-related
             assessments

          -  Subjects with current symptoms of severe, progressive, or uncontrolled renal,
             hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral
             disease, whether or not related to vitiligo and which, in the opinion of the
             investigator, might place a subject at unacceptable risk for participation in the
             study

          -  Subjects with a history of cancer in the last 5 years, other than non-melanoma skin
             cell cancers cured by local resection or carcinoma in situ. Existing non-melanoma
             skin cell cancers should be removed, the lesion site healed, and residual cancer
             ruled out before administration of the study drug

          -  Subjects who currently abuse drugs or alcohol

          -  Subjects with evidence (as assessed by the investigator) of active or latent
             bacterial or viral infections at the time of potential enrollment, including subjects
             with evidence of human immunodeficiency virus (HIV) detected during screening.

          -  Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months
             before the informed consent document was signed

          -  Subjects who have received any live vaccines within 3 months of the anticipated first
             dose of study medication

          -  Subjects with any serious bacterial infection within the last 3 months, unless
             treated and resolved with antibiotics, or any chronic bacterial infection (eg,
             chronic pyelonephritis, osteomyelitis, or bronchiectasis)

          -  Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be
             subjects with a history of active TB within the last 3 years, even if it was treated;
             a history of active TB greater than 3 years ago, unless there is documentation that
             the prior anti-TB treatment was appropriate in duration and type; current clinical,
             radiographic, or laboratory evidence of active TB; and latent TB that was not
             successfully treated (â‰¥ 4 weeks)

          -  Subjects must not be positive for hepatitis B surface antigen

          -  Subjects must not be positive for HIV

          -  Subjects who are positive for hepatitis C antibody if the presence of hepatitis C
             virus was also shown with polymerase chain reaction or recombinant immunoblot assay

          -  Subjects with any of the following laboratory values Hemoglobin &lt; 8.5 g/dL WBC &lt;
             3000/mm3 (&lt; 3 x 109/L) Platelets &lt; 100,000/mm3 (&lt; 3 x 109/L) Serum creatinine &gt; 2
             times the ULN Serum ALT or AST &gt; 2 times the ULN

          -  Any other laboratory test results that, in the opinion of the investigator, might
             place a subject at unacceptable risk for participation in the study

          -  Allergies to any components of abatacept or its vehicle

          -  Subjects who have at any time received treatment with any investigational drug within
             28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose

          -  Any concomitant biologic DMARD, such as anakinra

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (eg, infectious disease) illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaneeta Sheth, MD</last_name>
      <phone>617-732-4918</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 13, 2015</lastchanged_date>
  <firstreceived_date>October 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Victor Huang</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
